Is PT-141 (Bremelanotide) Legal in North Carolina?

The Short Answer on PT-141's Legal Status in North Carolina

PT-141 (Bremelanotide) is a legal prescription medication in North Carolina. The FDA approved Bremelanotide on June 21, 2019, under the brand name Vyleesi for treating HSDD in premenopausal women, making it a Schedule-unassigned, non-controlled prescription drug. [1] No North Carolina state statute bans or additionally restricts Bremelanotide beyond standard prescription-drug rules, so the federal framework governs entirely.

What "Legal" Actually Means Here

Legality for a prescription drug operates on two tracks. First, the FDA must have cleared the molecule for human use. Second, a licensed provider in good standing must issue a valid prescription. Bremelanotide clears both bars. What it does not permit is obtaining the compound without a prescription from a licensed North Carolina prescriber or from an out-of-state telehealth provider who has established a proper prescriber-patient relationship under NC General Statutes Chapter 90.

The Gray Area: Research-Grade PT-141

Some websites sell "research-grade" PT-141 labeled "not for human use." Buying that product for personal injection sits in a genuine legal gray area. The FDA has not placed Bremelanotide on its list of bulk substances that may be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act. [2] Using a research-chemical source bypasses the prescription requirement, which violates federal law regardless of what a vendor's disclaimer says.

FDA Approval and Federal Drug Law Framework

The FDA approved Vyleesi (Bremelanotide injection, 1.75 mg/0.3 mL) on June 21, 2019, based on two key Phase 3 trials (RECONNECT) in which Bremelanotide produced a statistically significant increase in satisfying sexual events and a decrease in distress scores compared to placebo over 24 weeks. [3] The prescribing information notes that the most common adverse effects are nausea (40%), flushing (20%), and injection-site bruising (11%). [1]

Federal Prescription Drug Status

Under 21 U.S.C. § 353(b), Bremelanotide requires a prescription because it is not safe for use without professional supervision. [4] That federal classification applies in all 50 states automatically, including North Carolina. There is no federal controlled-substance scheduling for PT-141, which means no DEA registration is required for a prescriber to write the script.

The 503A Compounding Issue

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound drugs for individual patients when they use bulk active pharmaceutical ingredients (APIs) on the FDA's approved 503A list. [5] Bremelanotide is not on that list. This single fact is the most important legal constraint on compounded PT-141 in North Carolina. A 503A pharmacy that compounds Bremelanotide from a bulk API is operating outside FDA guidance and could face enforcement.

Section 503B covers outsourcing facilities, which may compound under different rules but still cannot use bulk APIs not on the FDA's 503B list. [6] Bremelanotide is absent from that list as well. The practical result: any compounded PT-141 being sold in North Carolina exists outside the FDA's sanctioned compounding framework.

FDA Enforcement Posture

The FDA issued a 2023 import alert and a series of warning letters to compounders selling peptides, including Bremelanotide, as bulk research chemicals. [7] While the agency has not prosecuted individual patients who received compounded PT-141, the legal exposure sits with the pharmacy and potentially the prescriber, not the patient. Patients who order from unregistered foreign suppliers risk receiving adulterated product and may face U.S. Customs seizure under 21 C.F.R. Part 1.

North Carolina State Law and the NC Board of Pharmacy

North Carolina does not have a state-specific statute that separately schedules or bans Bremelanotide. The relevant North Carolina authority is the North Carolina Board of Pharmacy (NCBOP), which enforces both state pharmacy practice rules (21 NCAC Chapter 46) and federal drug law within the state. [8]

What the NCBOP Requires for Compounding

The NCBOP requires that any compounded preparation:

• Be made in response to a valid patient-specific prescription
• Use APIs from an FDA-registered supplier
• Comply with U.S. Pharmacopeia (USP) Chapter 795 or 797 standards for sterile preparations
• Not be a copy of a commercially available drug without a documented clinical reason

Vyleesi is commercially available. That fourth requirement is a meaningful barrier. A pharmacy that compounds Bremelanotide to circumvent the branded product's cost faces NCBOP scrutiny, and the prescriber who writes that script could face Medical Board review. [9]

North Carolina Medical Practice Act

Under NC General Statutes § 90-14, the NC Medical Board may discipline a physician for prescribing drugs "without a legitimate medical purpose or outside the course of professional practice." [10] Prescribing Bremelanotide for an off-label use such as sexual dysfunction in men is not automatically illegitimate, but the prescriber must document a thorough clinical rationale, patient history, and informed consent. Off-label prescribing of the branded Vyleesi product is legal; steering patients toward unregulated compounded versions carries more risk.

The HealthRX clinical team uses the following decision framework when evaluating PT-141 access requests from North Carolina patients:

1. Confirm an established prescriber-patient relationship (in-person or via compliant telehealth).
2. Screen for approved indication (HSDD in premenopausal women) or document off-label rationale.
3. Prescribe brand Vyleesi when insurance coverage or patient cost allows.
4. If cost is a barrier, note that compounded Bremelanotide is not on the 503A list and discuss the risk profile transparently with the patient.
5. Do not direct patients to research-chemical sources under any circumstances.

How to Get PT-141 Legally in North Carolina

Getting PT-141 legally in North Carolina follows the same path as any prescription medication. A licensed prescriber evaluates your clinical picture, determines that Bremelanotide is medically appropriate, and writes a prescription that a licensed pharmacy fills.

Step 1: Establish Care With a Licensed Prescriber

You can see a primary care physician, gynecologist, urologist, or sexual-health specialist in person anywhere in North Carolina. Telehealth is also an option. Under NC Session Law 2021-180, telehealth prescribing is permitted when the provider has established a valid prescriber-patient relationship, which typically involves a synchronous video or audio visit plus review of medical history. [11] A provider who prescribes solely on the basis of an online questionnaire without a live evaluation may not meet that standard.

Step 2: Obtain the Prescription

The prescriber submits the prescription electronically to a licensed pharmacy. For Vyleesi (1.75 mg auto-injector), most major retail pharmacies can fill it, though stock varies. The out-of-pocket cost for Vyleesi without insurance runs roughly $800 to $1,000 per month; the manufacturer (Palatin Technologies/AMAG Pharmaceuticals) has historically offered a co-pay assistance program. [12]

Step 3: Know Your Compounding Options and Their Limits

Some specialty and compounding pharmacies in North Carolina offer Bremelanotide in alternative forms, most commonly as a subcutaneous injectable reconstituted from lyophilized powder. Because Bremelanotide is not on the 503A bulk list, these preparations occupy a legally uncertain space. The NCBOP has not issued a state-specific enforcement notice as of this writing, but federal enforcement risk remains. Patients considering a compounded version should ask the pharmacy directly:

• Whether their API supplier is FDA-registered
• Whether they hold a current NCBOP pharmacy permit
• Whether their product has a certificate of analysis from a third-party lab

Lack of clear answers to any of those questions is a warning sign.

Telehealth Platforms and North Carolina

Several telehealth platforms operating nationwide write PT-141 prescriptions for North Carolina residents. Under federal Ryan Haight Act rules, a DEA-registered prescriber may prescribe controlled substances via telemedicine only under specific conditions, but Bremelanotide is not controlled, so that restriction does not apply. [13] The key requirement is that the telehealth provider holds an active North Carolina medical license or a multi-state compact license that covers North Carolina.

Clinical Profile: What PT-141 Actually Does

Understanding the pharmacology matters for setting realistic expectations. Bremelanotide is a melanocortin receptor agonist, specifically a cyclic heptapeptide that activates MC3R and MC4R receptors in the central nervous system. [14] Unlike phosphodiesterase-5 inhibitors (sildenafil, tadalafil), it does not act on vascular smooth muscle. Its mechanism is central rather than peripheral.

Efficacy Data From the RECONNECT Trials

The two key RECONNECT trials enrolled 1,267 premenopausal women with HSDD. At 24 weeks, Bremelanotide-treated patients reported a mean increase of 0.5 satisfying sexual events per month versus 0.2 for placebo (P<0.001) and a 0.3-point improvement on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) versus 0.1 for placebo. [3] The effect size is modest. The FDA-approved label states that Bremelanotide "is not intended to enhance sexual performance." [1]

Off-Label Use in Men

The RECONNECT trials enrolled only premenopausal women. Small studies suggest Bremelanotide may increase erectile function and sexual desire in men, including a Phase 2 trial (N=20) published in the International Journal of Impotence Research in 2000 by Wessells et al. [15] No Phase 3 male data exist. Prescribing Vyleesi off-label for men is legal in North Carolina, but the evidence base is thin, and no compounded PT-141 for men carries FDA sanction.

Dosing and Administration

The FDA-approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. [1] Patients should not take more than one dose in 24 hours, and no more than one dose every 15 days based on cardiovascular blood pressure data. Blood pressure can drop transiently, so patients with cardiovascular disease require special caution.

Risks of Obtaining PT-141 Outside Legal Channels

Buying PT-141 from a non-pharmacy, non-prescription source carries specific documented risks beyond the legal exposure.

Product Quality and Adulteration

Research-grade peptides are sold without USP sterility testing. A 2021 analysis published in JAMA Internal Medicine of compounded peptide products found that 18 of 22 samples (82%) failed identity, purity, or potency testing. [16] Injecting a contaminated product carries sepsis risk.

Cardiovascular Risk Without Screening

Bremelanotide is contraindicated in patients with known cardiovascular disease because it transiently increases blood pressure by approximately 2 to 4 mmHg systolic and decreases heart rate by 1 to 2 beats per minute. [1] Obtaining it without a prescriber means no screening for hypertension, coronary artery disease, or drug interactions (notably with naltrexone, which decreases Bremelanotide exposure by 35%). [1]

Hyperpigmentation

Transient facial flushing and focal hyperpigmentation occur in a small percentage of patients with prolonged use, particularly those with darker skin tones. The FDA label includes a specific warning. [1] Without clinical follow-up, this adverse effect may go unrecognized and worsen.

Insurance and Cost Considerations in North Carolina

Most commercial health plans in North Carolina do not cover Vyleesi for HSDD, classifying it as a "lifestyle" medication. However, some plans that cover flibanserin (Addyi), the other FDA-approved HSDD treatment, will cover Vyleesi after a prior authorization process. The NC Health Insurance Risk Pool and Medicaid typically do not cover it. Palatin Technologies offers a patient assistance program for individuals below 400% of the federal poverty level. [12]